GHENT, BELGIUM--(Marketwire - August 27, 2009) -
REGULATED INFORMATION
GHENT, Belgium, 27 August 2009 - Ablynx [Euronext Brussels: ABLX], announced today its results for the six month period ending 30 June 2009, which have been prepared in accordance with the IAS 34 ‘Interim Financial Reporting’ as adopted by the European Union.
H1 2009 Highlights
-- EUR 101.8 million in cash, cash equivalents and financial assets at 30 June 2009 -- 93% increase in revenues to EUR 11.9 million (2008: EUR 6.2 million) -- Reported detailed positive Phase Ib results in patients for its anti-thrombotic Nanobody® ALX-0081 and progressed to an extended Phase 1b study -- Ablynx’s vWF Nanobody® programme for the treatment of thrombotic thrombocytopenic purpura (TTP) was granted orphan drug designation in both Europe and the USA -- Announced a new preclinical development candidate, ALX-0061, a Nanobody® binding to IL6R, for the treatment of autoimmune and inflammatory diseases -- Announced important technology developments in pulmonary delivery and novel proprietary half-life extension of Nanobodies® -- Received a EUR 3 million milestone from Boehringer Ingelheim as part of the strategic alliance for the development and commercialisation of Nanobodies® -- Novartis and Wyeth Pharmaceuticals both extended their research collaborations with Ablynx for a further 12 months -- Ablynx strengthened its senior team with the appointment of a new Chief Scientific Officer, a Medical Director and a new Business Development Director -- Increased staff to over 220 people by period end -- Continued preparations for the move to new 7,000 m2 facility in mid-2010
Complete version of the press release in English: http://hugin.info/137912/R/1337716/318883.pdf
For more information, please contact: For international media enquiries: College Hill Life Sciences Sue Charles, Justine Lamond, Dr. John McIntyre t: +44 (0)20 7866 7857 e: ablynx@collegehill.com Ablynx: Dr. Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
For more information, please contact:
For international media enquiries:
College Hill Life Sciences
Sue Charles, Justine Lamond,
Dr. John McIntyre
t: +44 (0)20 7866 7857
e: Email Contact
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e: Email Contact
